# US 2023/0057622 A1 · Recombinant Human Neuregulin Derivatives and Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0057622 A1
- Document ID: US20230057622A1
- Status: Published application
- Kind: A1
- Application number: 17/642,855
- Filed: 2020-09-14
- Published: 2023-02-23
- Earliest claimed: 2019-09-16
- Assignees: Zensun (Shanghai) Science & Technology, Co., Ltd.
- Applicants: Zensun (Shanghai) Science & Technology, Co., Ltd.
- Inventors: Mingdong Zhou
- Web page: https://patentgrep.com/patent/US20230057622A1

## CPC

- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- C07K 14/4756: {Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07K 14/55: IL-2
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/02: containing a signal sequence
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed is a use of recombinant human neuregulin derivatives in preparing a medicine for preventing, treating, or reducing the progression of cardiovascular diseases in mammals. In particular, the present invention relates to a novel recombinant human NRG-FC protein and a use thereof in the treatment of cardiovascular diseases. The protein has a prolonged half-life and enhanced biological activity.

## Claims

### Claim 1

An NRG fusion polypeptide, comprising an amino acid sequence of an EGF-like domain of NRG and an amino acid sequence of an IgG Fc or Fc analogue.

### Claim 2 (depends on 1)

The NRG fusion polypeptide according to claim 1, wherein the amino acid sequence of the EGF-like domain of NRG is shown in the amino acid sequence of SEQ ID NO: 1 or an analogue thereof.

### Claim 3 (depends on 1)

The NRG fusion polypeptide according to claim 1, wherein the IgG Fc has the amino acid sequence of IgG1 or IgG4 subtype Fc or an analogue thereof.

### Claim 4 (depends on 3)

The NRG fusion polypeptide according to claim 3, further comprising a linker peptide sequence, and the EGF-like domain of NRG is linked to the IgG Fc through the linker peptide.

### Claim 5 (depends on 3)

The NRG fusion polypeptide according to claim 3, wherein the N-terminus of the polypeptide further comprises an amino acid sequence of an IL-2 signal peptide, and the amino acid sequence of the IL-2 signal peptide is cleaved during extracellular secretion of the recombinantly prepared NRG fusion polypeptide.

### Claim 6 (depends on 1)

The NRG fusion polypeptide according to claim 1, comprising an amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3.

### Claim 7

Use of an NRG fusion polypeptide in the manufacture of a medicament for preventing, treating or relieving cardiovascular diseases in mammals.

### Claim 8 (depends on 7)

The use according to claim 7, wherein the NRG fusion polypeptide comprises an amino acid sequence of an EGF-like domain of NRG, and an amino acid sequence of an IgG Fc or Fc analogue.

### Claim 9

A pharmaceutical formulation, comprising an NRG fusion polypeptide and a pharmaceutically acceptable carrier, excipient or diluent, wherein the NRG fusion polypeptide comprises an amino acid sequence of an EGF-like domain of NRG, and an amino acid sequence of an IgG Fc or Fc analogue.

### Claim 10

A method of treating cardiovascular diseases, comprising administering an effective dose of an NRG fusion polypeptide in an individual in need thereof, wherein the NRG fusion polypeptide comprises an amino acid sequence of an EGF-like domain of NRG, and an amino acid sequence of an IgG Fc or Fc analogue.
